CHAMBERLAIN UNIVERSITY
NR 546 Advanced
Pharmacology
Midterm Examination
ACTUAL EXAM TEST BANK
200 Questions and Correct Detailed Answers with Rationales
ALREADY GRADED A+
Aligned with NR 546 Course Objectives
Advanced Practice Nursing Pharmacology Standards
Graduate Nursing Education
Cognitive Distribution: 25% Recall | 55% Application | 20% Analysis
Question Style: 75% Scenario-Based | 25% Direct Recall
,NR 546 Advanced Pharmacology | Midterm Exam Test Bank Chamberlain University
Examination Contents
Section Domain Questions Count
1 Advanced Pharmacokinetics & Pharmacodynamics Q1 – Q25 25
2 Pharmacogenomics, Drug Interactions, Individualized Prescribing Q26 – Q50 25
3 Cardiovascular Pharmacology Q51 – Q99 49
4 Endocrine Pharmacology Q100 – Q131 32
5 Antimicrobial Pharmacology Q132 – Q158 27
6 CNS & Psychiatric Pharmacology Q159 – Q183 25
7 Prescriptive Practice, Special Populations, Monitoring Q184 – Q200 17
TOTAL 200
Examination Instructions: This midterm examination consists of 200 multiple-choice questions spanning seven core
domains of advanced pharmacology. Each question has one best answer. Detailed rationales accompany each question with
pharmacokinetic, pharmacodynamic, evidence-based, and prescriptive safety reasoning. Cognitive distribution: 25% recall,
55% application, 20% analysis.
200 Questions & Detailed Answers with Rationales Page 2
,NR 546 Advanced Pharmacology | Midterm Exam Test Bank Chamberlain University
Section 1: Advanced Pharmacokinetics and Pharmacodynamics
Absorption, Distribution, Metabolism, Excretion, Receptors, & Dose-Response (Q1–Q25)
Q1: A 68-year-old patient with cirrhosis is prescribed a medication that is normally 95% metabolized by
first-pass hepatic metabolism. Which pharmacokinetic change is most expected, and what is the safest
prescribing implication?
A. Bioavailability decreases; the dose should be increased to compensate.
B. Bioavailability increases; the dose should be reduced to avoid toxicity. [CORRECT]
C. Distribution is unchanged; only the dosing interval needs extension.
D. Renal clearance compensates; no dose adjustment is needed.
Correct Answer: B
Rationale: In cirrhosis, impaired first-pass hepatic metabolism reduces drug extraction before systemic circulation,
increasing bioavailability of highly extracted drugs (e.g., propranolol, morphine). The correct response is to reduce the dose
to prevent supra-therapeutic plasma concentrations. Distribution and renal clearance are not reliably affected in early
cirrhosis, and the dosing interval alone does not correct for elevated peak concentration.
Q2: A patient receives a drug with a narrow therapeutic index (TI = 2). Which statement best describes the
clinical implication of this index and the prescriber's monitoring obligation?
A. The drug has a wide safety margin; routine monitoring is optional.
B. Toxic dose is only twice the therapeutic dose; serum drug levels must be monitored. [CORRECT]
C. Half-life is short; dosing frequency must exceed every 4 hours.
D. Bioavailability exceeds 90%; dose reduction is contraindicated.
Correct Answer: B
Rationale: Therapeutic Index (TI) = Toxic Dose 50 / Effective Dose 50. A TI of 2 means the toxic dose is only twice the
effective dose, signaling a narrow safety margin requiring therapeutic drug monitoring (e.g., digoxin, lithium, phenytoin,
warfarin). TI does not predict half-life, bioavailability, or dosing frequency. Dose reduction is not universally
contraindicated but must be guided by serum concentrations.
Q3: Which statement correctly describes the relationship between volume of distribution (Vd), lipophilicity,
and dosing in an obese patient?
A. Lipophilic drugs have a small Vd and require dosing based on ideal body weight.
B. Lipophilic drugs have a large Vd and may require dosing based on total body weight. [CORRECT]
C. Hydrophilic drugs distribute widely into adipose tissue and require weight-based loading doses.
D. Vd is independent of lipophilicity and is determined solely by renal function.
Correct Answer: B
Rationale: Lipophilic drugs (e.g., propofol, fentanyl, diazepam, amiodarone) distribute extensively into adipose tissue,
producing a large Vd that may necessitate dosing based on total body weight or adjusted body weight. Hydrophilic drugs
(e.g., gentamicin, vancomycin) distribute into extracellular water and are typically dosed on ideal or adjusted body weight in
obesity. Vd is a property of drug and physiology, not renal function alone.
Q4: A drug follows first-order kinetics. After four half-lives, what percentage of the original dose remains in
the body, and when is steady state approximately achieved during continuous dosing?
200 Questions & Detailed Answers with Rationales Page 3
, NR 546 Advanced Pharmacology | Midterm Exam Test Bank Chamberlain University
A. 6.25% remains; steady state is reached in 4–5 half-lives. [CORRECT]
B. 25% remains; steady state is reached in 2 half-lives.
C. 50% remains; steady state is reached in 1 half-life.
D. 12.5% remains; steady state is reached in 10 half-lives.
Correct Answer: A
Rationale: First-order elimination removes a constant fraction per half-life. After 4 half-lives, 6.25% (1/16) of the original
dose remains. Steady state during continuous dosing is achieved in approximately 4–5 half-lives because the rate of
elimination equals the rate of administration. This principle guides timing of therapeutic drug monitoring (e.g., wait 4–5
half-lives before checking trough levels after a dose change).
Q5: A patient on phenytoin therapy has a serum concentration of 8 mcg/mL (therapeutic range 10–20
mcg/mL). The prescriber increases the dose by 25%, but the new level is 28 mcg/mL (toxic). What
pharmacokinetic property explains this disproportionate response?
A. First-order kinetics; dose increase proportionally raises level.
B. Zero-order (Michaelis-Menten) kinetics; metabolism saturates near therapeutic range. [CORRECT]
C. Linear kinetics; level doubles with each dose increment.
D. Renal clearance saturation; level depends on creatinine clearance.
Correct Answer: B
Rationale: Phenytoin exhibits Michaelis-Menten (saturable, zero-order) kinetics. As dose approaches the maximum
metabolic capacity (Vmax), small dose increments produce disproportionate increases in serum concentration because the
elimination pathway becomes saturated. This is why phenytoin requires level-guided titration in small increments (e.g.,
30–100 mg) rather than proportional increases. First-order kinetics would predict a linear, proportional response.
Q6: A drug has an elimination half-life of 12 hours. To rapidly achieve therapeutic levels in an acutely
symptomatic patient, the prescriber orders a loading dose. What is the pharmacokinetic rationale for this
strategy?
A. Loading dose bypasses first-pass metabolism to maximize bioavailability.
B. Loading dose rapidly fills the volume of distribution to achieve target steady-state concentration. [CORRECT]
C. Loading dose shortens the drug's half-life to allow more frequent dosing.
D. Loading dose inhibits CYP3A4 to prolong the elimination phase.
Correct Answer: B
Rationale: Loading dose = (Target Css × Vd) / Bioavailability. It rapidly fills the apparent volume of distribution so the
target plasma concentration is achieved before the 4–5 half-lives required by maintenance dosing alone. With a 12-hour
half-life, steady state would take 48–60 hours — too slow for symptomatic relief. Loading does not alter bioavailability,
half-life, or CYP activity.
Q7: A patient taking a medication that is a substrate of P-glycoprotein (P-gp) is started on a P-gp inhibitor.
Which pharmacokinetic consequence is most likely, and which drug pair exemplifies this interaction?
A. Decreased absorption; bioavailability falls (e.g., rifampin + digoxin).
B. Increased absorption and reduced renal/biliary excretion; toxicity risk rises (e.g., clarithromycin + digoxin).
[CORRECT]
C. Increased first-pass metabolism; effect is attenuated (e.g., phenytoin + warfarin).
D. Induction of CYP3A4; therapeutic effect is lost (e.g., carbamazepine + oral contraceptives).
Correct Answer: B
200 Questions & Detailed Answers with Rationales Page 4
NR 546 Advanced
Pharmacology
Midterm Examination
ACTUAL EXAM TEST BANK
200 Questions and Correct Detailed Answers with Rationales
ALREADY GRADED A+
Aligned with NR 546 Course Objectives
Advanced Practice Nursing Pharmacology Standards
Graduate Nursing Education
Cognitive Distribution: 25% Recall | 55% Application | 20% Analysis
Question Style: 75% Scenario-Based | 25% Direct Recall
,NR 546 Advanced Pharmacology | Midterm Exam Test Bank Chamberlain University
Examination Contents
Section Domain Questions Count
1 Advanced Pharmacokinetics & Pharmacodynamics Q1 – Q25 25
2 Pharmacogenomics, Drug Interactions, Individualized Prescribing Q26 – Q50 25
3 Cardiovascular Pharmacology Q51 – Q99 49
4 Endocrine Pharmacology Q100 – Q131 32
5 Antimicrobial Pharmacology Q132 – Q158 27
6 CNS & Psychiatric Pharmacology Q159 – Q183 25
7 Prescriptive Practice, Special Populations, Monitoring Q184 – Q200 17
TOTAL 200
Examination Instructions: This midterm examination consists of 200 multiple-choice questions spanning seven core
domains of advanced pharmacology. Each question has one best answer. Detailed rationales accompany each question with
pharmacokinetic, pharmacodynamic, evidence-based, and prescriptive safety reasoning. Cognitive distribution: 25% recall,
55% application, 20% analysis.
200 Questions & Detailed Answers with Rationales Page 2
,NR 546 Advanced Pharmacology | Midterm Exam Test Bank Chamberlain University
Section 1: Advanced Pharmacokinetics and Pharmacodynamics
Absorption, Distribution, Metabolism, Excretion, Receptors, & Dose-Response (Q1–Q25)
Q1: A 68-year-old patient with cirrhosis is prescribed a medication that is normally 95% metabolized by
first-pass hepatic metabolism. Which pharmacokinetic change is most expected, and what is the safest
prescribing implication?
A. Bioavailability decreases; the dose should be increased to compensate.
B. Bioavailability increases; the dose should be reduced to avoid toxicity. [CORRECT]
C. Distribution is unchanged; only the dosing interval needs extension.
D. Renal clearance compensates; no dose adjustment is needed.
Correct Answer: B
Rationale: In cirrhosis, impaired first-pass hepatic metabolism reduces drug extraction before systemic circulation,
increasing bioavailability of highly extracted drugs (e.g., propranolol, morphine). The correct response is to reduce the dose
to prevent supra-therapeutic plasma concentrations. Distribution and renal clearance are not reliably affected in early
cirrhosis, and the dosing interval alone does not correct for elevated peak concentration.
Q2: A patient receives a drug with a narrow therapeutic index (TI = 2). Which statement best describes the
clinical implication of this index and the prescriber's monitoring obligation?
A. The drug has a wide safety margin; routine monitoring is optional.
B. Toxic dose is only twice the therapeutic dose; serum drug levels must be monitored. [CORRECT]
C. Half-life is short; dosing frequency must exceed every 4 hours.
D. Bioavailability exceeds 90%; dose reduction is contraindicated.
Correct Answer: B
Rationale: Therapeutic Index (TI) = Toxic Dose 50 / Effective Dose 50. A TI of 2 means the toxic dose is only twice the
effective dose, signaling a narrow safety margin requiring therapeutic drug monitoring (e.g., digoxin, lithium, phenytoin,
warfarin). TI does not predict half-life, bioavailability, or dosing frequency. Dose reduction is not universally
contraindicated but must be guided by serum concentrations.
Q3: Which statement correctly describes the relationship between volume of distribution (Vd), lipophilicity,
and dosing in an obese patient?
A. Lipophilic drugs have a small Vd and require dosing based on ideal body weight.
B. Lipophilic drugs have a large Vd and may require dosing based on total body weight. [CORRECT]
C. Hydrophilic drugs distribute widely into adipose tissue and require weight-based loading doses.
D. Vd is independent of lipophilicity and is determined solely by renal function.
Correct Answer: B
Rationale: Lipophilic drugs (e.g., propofol, fentanyl, diazepam, amiodarone) distribute extensively into adipose tissue,
producing a large Vd that may necessitate dosing based on total body weight or adjusted body weight. Hydrophilic drugs
(e.g., gentamicin, vancomycin) distribute into extracellular water and are typically dosed on ideal or adjusted body weight in
obesity. Vd is a property of drug and physiology, not renal function alone.
Q4: A drug follows first-order kinetics. After four half-lives, what percentage of the original dose remains in
the body, and when is steady state approximately achieved during continuous dosing?
200 Questions & Detailed Answers with Rationales Page 3
, NR 546 Advanced Pharmacology | Midterm Exam Test Bank Chamberlain University
A. 6.25% remains; steady state is reached in 4–5 half-lives. [CORRECT]
B. 25% remains; steady state is reached in 2 half-lives.
C. 50% remains; steady state is reached in 1 half-life.
D. 12.5% remains; steady state is reached in 10 half-lives.
Correct Answer: A
Rationale: First-order elimination removes a constant fraction per half-life. After 4 half-lives, 6.25% (1/16) of the original
dose remains. Steady state during continuous dosing is achieved in approximately 4–5 half-lives because the rate of
elimination equals the rate of administration. This principle guides timing of therapeutic drug monitoring (e.g., wait 4–5
half-lives before checking trough levels after a dose change).
Q5: A patient on phenytoin therapy has a serum concentration of 8 mcg/mL (therapeutic range 10–20
mcg/mL). The prescriber increases the dose by 25%, but the new level is 28 mcg/mL (toxic). What
pharmacokinetic property explains this disproportionate response?
A. First-order kinetics; dose increase proportionally raises level.
B. Zero-order (Michaelis-Menten) kinetics; metabolism saturates near therapeutic range. [CORRECT]
C. Linear kinetics; level doubles with each dose increment.
D. Renal clearance saturation; level depends on creatinine clearance.
Correct Answer: B
Rationale: Phenytoin exhibits Michaelis-Menten (saturable, zero-order) kinetics. As dose approaches the maximum
metabolic capacity (Vmax), small dose increments produce disproportionate increases in serum concentration because the
elimination pathway becomes saturated. This is why phenytoin requires level-guided titration in small increments (e.g.,
30–100 mg) rather than proportional increases. First-order kinetics would predict a linear, proportional response.
Q6: A drug has an elimination half-life of 12 hours. To rapidly achieve therapeutic levels in an acutely
symptomatic patient, the prescriber orders a loading dose. What is the pharmacokinetic rationale for this
strategy?
A. Loading dose bypasses first-pass metabolism to maximize bioavailability.
B. Loading dose rapidly fills the volume of distribution to achieve target steady-state concentration. [CORRECT]
C. Loading dose shortens the drug's half-life to allow more frequent dosing.
D. Loading dose inhibits CYP3A4 to prolong the elimination phase.
Correct Answer: B
Rationale: Loading dose = (Target Css × Vd) / Bioavailability. It rapidly fills the apparent volume of distribution so the
target plasma concentration is achieved before the 4–5 half-lives required by maintenance dosing alone. With a 12-hour
half-life, steady state would take 48–60 hours — too slow for symptomatic relief. Loading does not alter bioavailability,
half-life, or CYP activity.
Q7: A patient taking a medication that is a substrate of P-glycoprotein (P-gp) is started on a P-gp inhibitor.
Which pharmacokinetic consequence is most likely, and which drug pair exemplifies this interaction?
A. Decreased absorption; bioavailability falls (e.g., rifampin + digoxin).
B. Increased absorption and reduced renal/biliary excretion; toxicity risk rises (e.g., clarithromycin + digoxin).
[CORRECT]
C. Increased first-pass metabolism; effect is attenuated (e.g., phenytoin + warfarin).
D. Induction of CYP3A4; therapeutic effect is lost (e.g., carbamazepine + oral contraceptives).
Correct Answer: B
200 Questions & Detailed Answers with Rationales Page 4
